Skip to content
value.today

HOOKIPA Pharma Inc.

🇺🇸 New York, New York, USAPharmaceuticalsFounded 2017
Total raised
$37 M
1 round on record
Latest round
$37 M
Feb 2019
First round on record
Feb 2019
Today
Private
No later event on record

Funding rounds

1 counted as startup funding. Open the number of investors for the round's details.

Funding rounds of HOOKIPA Pharma Inc.
MonthRaisedRaiseSizeInvestorsSoldFiling
Feb 2019$37 MNo. 1$10 to $50 million

HOOKIPA Pharma Inc.: Raise no. 1, Feb 2019

Investors in this round

9 investors had bought by the notice of Feb 27, 2019: 9 accredited, none not accredited.

Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round. 6 investors are named for HOOKIPA Pharma Inc. as a whole in other filings: see Investors below.

What the notice says

Amount sold
$37 M (amount offered: indefinite)
Smallest investment taken
no minimum stated
What was sold
equity
Exemption claimed
  • Rule 506(b): a private sale without public advertising; up to 35 buyers may be non-accredited
Meant to last
a year or less
Issuer's revenue
Not disclosed
Sales commissions
none
Finders' fees
none
Paid to its own people
none (proceeds used for payments to executives, directors or promoters)
The company
Corporation, incorporated in Delaware

People named in the notice

  • Joern Aldag · Executive Officer, Director
  • Reinhard Kandera · Executive Officer, Director
  • Christoph Lengauer · Director
  • Graziano Seghezzi · Director
  • Jan van de Winkel · Director
  • Julie O'Neill · Director
  • Michael Kelly · Director
  • Paul-Henri Lambert · Director
  • Sander van Deventer · Director

Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.

Paid to sell the round

No one: the notice names no broker or finder paid to sell it.

Signed by Joern Aldag, President. Source: SEC Form D, newest notice filed Feb 27, 2019. Read the notice at the SEC.

equitySEC

Source: SEC Form D. Each row is one private sale of securities with the running total of its newest notice. The form does not name the series or the investors; rounds are numbered in the order they were filed. A round's details show what its notice does say: accredited and other investors, the smallest investment taken, the exemption claimed, fees, the people named and the brokers paid to sell it.

How it makes money#

What its filings and its own website say, sentence by sentence, each with its source.

  • HOOKIPA Pharma Inc. chose not to state its revenue in its newest notice of a funding round (Feb 2019).

    SEC Form D · Feb 2019

  • The industry group it chose in its notices: Pharmaceuticals.

    SEC Form D · Feb 2019

That is all the official record says: HOOKIPA Pharma Inc. has not published its revenue in a filing we can read, and no other official source covers it. Revenue figures come from crowdfunding filings (SEC Form C) and from annual reports once a company is listed.

Products and services#

No products or services on record: no website is on record for it in an official source (its SEC filings, Wikidata).

Investors#

6 named in official filings. Open an investor to see everything it has backed.

Investors in HOOKIPA Pharma Inc.
InvestorKindAmountRoundRoleSource
Baker Bros. Advisors (GP) LLCFund or asset managernot statednot statedHeld Series C and D preferred stock, 10% owner (Form 3, 2019)SEC Form 3
Baker Bros. Advisors LPFund or asset managernot statednot statedHeld Series C and D preferred stock, 10% owner (Form 3, 2019)SEC Form 3
Forbion Capital Fund II Cooperatief U.A.Fund or asset managernot statednot statedHeld Series A, B and C preferred stock, 10% owner (Form 3, 2019)SEC Form 3
Redmile Group, LLCFund or asset managernot statednot statedHeld Series D preferred stock, 10% owner (Form 3, 2019)SEC Form 3
Sofinnova Capital VI FcprFund or asset managernot statednot statedHeld Series A, B and C preferred stock, 10% owner (Form 3, 2019)SEC Form 3
Sofinnova Partners SASFund or asset managernot statednot statedHeld Series A, B and C preferred stock, 10% owner (Form 3, 2019)SEC Form 3

Source: SEC Form 3 statements, SEC Form N-PORT fund reports, Wikidata, value.today research. Names come from filings that do name holders: the preferred stock each holder had when the company registered its shares (Form 3), private shares in US mutual funds' portfolio reports (N-PORT), and Wikidata. None ties a name to one funding round, so this list is per company, and it is not complete: the 1 round above had up to 9 investors.

Executives and directors

As the company named them in its notices. Directors of a funded startup are often partners of its investors.

People named by HOOKIPA Pharma Inc.
NameRoleNamed in
Joern AldagExecutive officerFeb 2019
Reinhard KanderaExecutive officerFeb 2019
Christoph LengauerDirectorFeb 2019
Graziano SeghezziDirectorFeb 2019
Jan van de WinkelDirectorFeb 2019
Joern AldagDirectorFeb 2019
Julie O'NeillDirectorFeb 2019
Michael KellyDirectorFeb 2019
Paul-Henri LambertDirectorFeb 2019
Reinhard KanderaDirectorFeb 2019
Sander van DeventerDirectorFeb 2019